Compare ACDC & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | FLGT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.3M | 867.4M |
| IPO Year | 2021 | 2016 |
| Metric | ACDC | FLGT |
|---|---|---|
| Price | $6.46 | $15.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.83 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 1.4M | 760.3K |
| Earning Date | 03-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,941,800,000.00 | $18,730,000.00 |
| Revenue This Year | N/A | $10.66 |
| Revenue Next Year | $6.37 | $12.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $13.46 |
| 52 Week High | $10.70 | $31.04 |
| Indicator | ACDC | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 34.09 |
| Support Level | $3.48 | $13.46 |
| Resistance Level | $7.47 | $22.48 |
| Average True Range (ATR) | 0.49 | 0.64 |
| MACD | 0.08 | 0.37 |
| Stochastic Oscillator | 56.05 | 91.86 |
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.